פרבליפ 40
unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and nor
פרבליפ 10
unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal
פטריון
rafa laboratories ltd - miconazole nitrate - קרם - miconazole nitrate 2 % - miconazole - miconazole - skin and nail infections due to dermatophytes or candida.
פונגידרם
rafa laboratories ltd - miconazole nitrate - קרם - miconazole nitrate 2 % - miconazole - miconazole - skin and nail infections due to dermatophytes or candida.
פניסטיל ג'ל
gsk consumer healthcare, israel ltd - dimetindene maleate - ג'ל - dimetindene maleate 0.1 %w/w - dimetindene - dimetindene - urticaria, pruritis, dermatoses, burns, insect bites, allergic dermatitis and eczema.
רוזקס
a.m.i. medical technologies limited, israel - metronidazole - ג'ל - metronidazole 7.5 mg/g - metronidazole - metronidazole - topical application for the treatment of inflammatory papules, pustules and erythema of rosacea.
בטנובט תמיסה לקרקפת
glaxo smith kline (israel) ltd - betamethasone as valerate - תמיסה - betamethasone as valerate 0.1 %w/w - betamethasone - betamethasone - treatment of steroid responsive dermatoses of the scalp such as psoriasis and seborrheic dermatitis.
בטאקורטן תמיסה לקרקפת
trima israel pharmaceutical products maabarot ltd - betamethasone as valerate - תמיסה - betamethasone as valerate 0.1 %w/w - betamethasone - betamethasone - a specific treatment for dermatoses of the scalp.
דרמובט תמיסה לקרקפת
glaxo smith kline (israel) ltd - clobetasol propionate - תמיסה - חיצוני - clobetasol propionate 0.05 %w/w - clobetasol - clobetasol - for the topical treatment of inflammatory conditions of the scalp responsive only to corticosteroids.
אדפרין קרם
a.m.i. medical technologies limited, israel - adapalene - קרם - adapalene 0.1 %w/w - adapalene - adapalene - for the cutaneous treatment of acne vulgaris, where comedones, papules and postules predominate. acne of the face, chest or back is appropriate for treatment. the treatment is limited up to six months in adolescents over 12 years.